Allied Minds Names Joseph Pignato As Chief Financial Officer

BOSTON--(BUSINESS WIRE)--Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announced that Joseph Pignato is joining its executive management team as Chief Financial Officer.

"It's a privilege to join Allied Minds, a company that brings together a unique mix of entrepreneurial talent and seasoned, global expertise"

Joe's experience as a senior advisor to fast-growing businesses spans almost two decades. After gaining experience in accounting at PKF Worldwide and Deloitte, Joe developed expertise in the effective deployment of venture capital for early stage companies during his tenure as CFO of Charles River Ventures; as General Partner, Chief Operating Officer and CFO of Prism Ventures; and as a Board Member of the Slater Technology Fund. Joe also applied his own skills in value creation while serving as Director of Finance at Lightbridge, a NASDAQ-listed firm that he helped to take public; and as CFO at Swipely, which grew to more than $4 billion in sales under management during his tenure.

"It's a privilege to join Allied Minds, a company that brings together a unique mix of entrepreneurial talent and seasoned, global expertise," said Joe. "Allied Minds' dynamic and fast-moving environment is exciting, and I look forward to working with the team to help develop and support new companies in their innovative, and potentially market-disruptive, work."

Joe's broad strengths in finance, investor relations and operations, as well as his skills as a mentor to management teams, will be an asset to Allied Minds and its 22 subsidiary companies. At Allied Minds, Joe is joining an expanding team of experienced senior managers who are engaged in advising the portfolio companies on how to navigate high-growth strategies as they commercialize sophisticated technologies developed at U.S. federal and academic research centers.

"Joe brings a robust track record of managing and fostering early stage companies into financial stability and growth," said Chris Silva, Chief Executive Officer of Allied Minds. "I am confident that he will further enhance our ability to transform U.S. inventions into commercial innovation. We are delighted to have him on board the Allied Minds team."

More information about Allied Minds can be found at www.alliedminds.com.

About Allied Minds, Inc.

Allied Minds is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
ArcPoint Strategic Communications
Christine Dunn, 617-484-1660 x101
[email protected]

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.